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Elevated expression and/or activity of c-Src, the prototype of the Src family of protein tyrosine kinases, is associated with the
development of human colon cancer. However, despite the known pleiotropic effects of these kinases in promoting (a) cell
growth downstream of growth factor receptors, and (b) the dynamic regulation of integrin adhesions in ﬁbroblast model
systems, their precise role in epithelial cancer cells is unknown. Here we addressed whether elevated expression and activity
of cellular Src alters cell proliferation and/or cell–matrix adhesion in cancer cells from the Fidler model of colorectal
metastasis. Although elevated Src correlates with ability to metastasise to the liver after intrasplenic injection, we found that
this was not linked to enhanced growth, either in vitro or in vivo as sub-cutaneous tumours. However, elevated Src was
associated with enhanced attachment to extracellular matrix. In addition, adhesion to ﬁbronectin, was suppressed by agents
that inhibited Src activity, while enforced elevation of Src in non-metastatic cells was sufﬁcient to stimulate adhesion to
ﬁbronectin and enhanced assembly of adhesion complexes, without inﬂuencing cell growth. Thus, we conclude that one role
of elevated Src in human colon cancer cells is to modulate integrin-dependent cell–matrix attachment and formation of
adhesion structures, which may, in turn, inﬂuence cell motility and integrin-dependent cellular responses.
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Although metastatic spread is the major cause of death in cancer
patients, the molecular mechanisms that control key steps in the
dissemination process remain elusive. Although analysis of cancer
cells derived from metastases is not, by itself, able to decipher
the metastatic process, understanding how individual oncopro-
teins or tumour suppressor proteins contribute to the
fundamental biological changes that accompany metastasis, can
provide insight into the control of events that promote metasta-
sis. In this regard, cellular models, such as that provided by the
Fidler model of colorectal metastasis (Morikawa et al, 1988),
provide tractable reductionist systems. Here we have used cancer
cells from the Fidler model to speciﬁcally address the behavioural
changes associated with elevated expression and activity of the c-
Src tyrosine kinase that frequently occurs in metastatic colorectal
cells.
A number of studies have demonstrated elevated cellular
activity of c-Src, the prototypic member of the Src family of
protein tyrosine kinases, during colorectal tumour progression,
with an increasing trend from adenomas through to malignant
carcinomas and metastases (Bolen et al, 1987; Cartwright et al,
1989, 1990, 1994; Talamonti et al, 1993; Termuhlen et al,
1993). It was also recently reported that an activating mutation
of c-Src, at tyrosine 527 in the carboxy-terminal regulatory
region, occurred in a sub-set of advanced, metastatic colon
cancers (Irby et al, 1999). However, mutational activation of
c-Src has not been found in other similar studies (Daigo et
al, 1999; Wang et al, 2000a; Laghi et al, 2001), and so there
remains uncertainty about the mode of c-Src elevation in color-
ectal cancer cells. Here we address how c-Src contributes to the
behaviour of colorectal cancer cells, speciﬁcally asking whether
elevated cellular c-Src activity alters colon cancer cell growth
and/or adhesion, two properties that are inﬂuenced by Src in
model cell systems and that are frequently altered during color-
ectal cancer progression.
Studies over many years in ﬁbroblast model systems have impli-
cated the Src family kinases (SFKs) in growth factor mediated
mitogenic responses (Twamley et al, 1993; Roche et al, 1995).
Speciﬁcally, c-Src is required for platelet-derived growth factor
(PDGF)-induced mitogenesis (Roche et al, 1995; Twamley et al,
1993), most likely via its induction of a Stat3/c-Myc pathway
(Barone and Courtneidge, 1995; Broome and Hunter, 1996; Wang
et al, 2000b; Bowman et al, 2001). Also, v-Src can induce mitogen-
esis in serum-deprived ﬁbroblasts (Welham et al, 1990) as well as
promote the G1/S phase transition in growing transformed cells
(Johnson et al, 1998).
There is considerable evidence that c-Src can also regulate adhe-
sion dynamics by both kinase-dependent and kinase-independent
mechanisms. Exogenous expression of c-Src can stimulate cell–
matrix adhesion of c-Src 7/7 ﬁbroblasts by a mechanism that
is independent of its catalytic activity (Kaplan et al, 1995), while
kinase-independent functions of v-Src are required for its incor-
poration into newly assembling integrin adhesions (Fincham and
Frame, 1998; Fincham et al, 2000). Recent work also showed that
cells derived from triple Src/Fyn/Yes null embryos display impaired
motility (Klinghoffer et al, 1999), while the dominant negative
effect of kinase-deﬁcient v-Src suppresses adhesion turnover and
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are not mutually exclusive and SFK activity at the cell membrane
may co-ordinate adhesion dependent growth responses. Here we
have addressed whether elevated c-Src in metastatic cells correlates
with enhanced growth or enhanced cell–matrix adhesion, and
whether expression of exogenous active c-Src in the non-metastatic
cells is sufﬁcient to induce either of these.
MATERIALS AND METHODS
Cell culture and cell lines
Cell lines KM12 C, KM12 SM and KM12 L4A were a kind gift
from Professor I Fidler (MD Anderson, TX, USA) and the RGC2
cells were a gift from Professor C Paraskeva (Bristol, UK). KM12
cells were cultured in Eagles MEM with Earle’s salts supplemented
with MEM vitamins (62), non-essential amino acids, L-glutamine
(2 mM) and sodium pyruvate (1 mM) (all from Life Technologies,
Paisley, UK) in the presence of 10% foetal bovine serum (Autogen
Bioclear, Wiltshire, UK). RGC2 cells were cultured in Dulbecco’s
modiﬁed Eagle’s medium with hydrochloric acid (4 mM), sodium
bicarbonate (0.075%), glutamine (2 mM), (Life Technologies)
supplemented with 20% foetal bovine serum (Autogen Bioclear),
insulin (10 mgm l
71, Roche Diagnostics Ltd, Lewes, UK) and
hydrocortisone (1 mgm l
71, Sigma Chemical Company). All cells
were routinely maintained in a humidiﬁed incubator at 378C with
5% CO2 and sub-cultured before reaching conﬂuence.
KM12C cells were transfected using the Lipofectamine Plus
reagent (Life Technologies) and stable cell lines derived after selec-
tion of single cell clones. The cDNA expression vector, pUSE
(Upstate Biotechnology) was used to derive cell lines expressing
the vector alone and active c-Src (Y527F).
Anchorage-independent growth
Culture medium containing 20% serum, 50 U ml
71 penicillin,
250 mgm l
71 streptomycin and 0.6% Agar was prepared. Four ml
of agar/medium was placed into 60 mm tissue culture dishes and
allowed to solidify (base agar). Cells were re-suspended at
5610
2 cells ml
71 in medium containing 0.3% agar and 2 ml layered
on top of the base agar. Colony growth was recorded after 7 days.
Tumourigenicity assay
Cells for injection were resuspended in Hanks’ buffered saline solu-
tion (HBSS) at 378C prior to subcutaneous injection of
2610
6 cells in 100 ml of HBSS into the right ﬂank of 4–6-week-
old female nude mice (Charles Rivers, Harlan, UK). Bidimensional
tumour measurements were made every 5 days using callipers and
the average of these measurements used as an estimate of the
diameter of a sphere in order to calculate tumour volume.
Immunoblotting and immunoprecipitation
Cell extracts were prepared in RIPA buffer (50 mM Tris, 150 mM
NaCl, 1% NP40, 0.5% deoxycholate, 0.1% SDS, pH 7.4) from
sub-conﬂuent cell cultures and clariﬁed by centrifugation at 48C.
Total protein was measured using microBCA reagent (Pierce,
Rockford, IL, USA). Immunoprecipitates of c-Src phosphorylated
on tyrosine-416 were prepared by incubating 1.5 mg of cell lysate
with 2 mg of polyclonal phosphotyrosine-416-c-Src-speciﬁc anti-
body (Biosource International, Camarillo, CA, USA) overnight.
Paxillin immunoprecipitates were prepared from 1 mg of protein
with 4 mg anti-paxillin antibody (Transduction Laboratories,
Lexington, KY, USA). Immune-complexes were collected using
protein A sepharose (Sigma Chemical Company, Poole, UK) and
washed extensively with lysis buffer. Proteins were resolved by
10% (c-Src) and 6% (phospho 416 Src) SDS–PAGE gels respec-
tively, and transferred to nitrocellulose membranes prior to
visualisation using anti-v-Src mAb (Ab-1) (0.1 mgm l
71, Oncogene
Research Products, Cambridge, MA, USA). Paxillin immunopreci-
pitates were resolved by 7% SDS–PAGE gels prior to transfer and
probed with anti-phosphotyrosine mAB PY20 (1 mgm l
71, Trans-
duction Laboratories). Blots were subsequently stripped and
reprobed with anti-paxillin antibody (25 ng ml
71). For immuno-
blotting, 50 mg cellular protein were resolved as above.
Immune-complex kinase assays
Anti-c-Src from 200 mg cell lysate was immunoprecipitated with 2 mg
EC10, collected on protein A-sepharose beads, washed extensively
and assayed for protein kinase activity using 10 mg exogenous enolase
as substrate. The kinase assay buffer was 20 mM PIPES pH 6.4,
20 mM MnCl2,1m M DTT, 100 mM sodium orthovanadate, with
10 mM ATP and 5 mCi ATP-[P
32] (speciﬁc activity 3000 Cimmol
71).
Incubation was for 10 min at 308C, and the reaction was stopped by
addition of SDS–PAGE sample buffer and boiling, prior to resolving
proteins by SDS–PAGE. SU6656 was dissolved in DMSO to 10 mM
stock, and diluted in cell culture medium. A similar amount of
DMSO solvent was added to control cells.
Microscopy and immunoﬂuorescence
Glass coverslips were pre-coated with human ﬁbronectin (Becton
Dickinson, Bedford, MA, USA) or poly-L-lysine (Sigma) at 378C
for 90 min (10 mgm l
71 in phosphate buffered saline) and washed
in PBS. Cells were plated for 60 min and ﬁxed for 15 min in 3.7%
formaldehyde at room temperature. After permeabilisation with
0.5% Triton X-100 for 10 min, cells were blocked with 10% foetal
bovine serum before incubating overnight with anti-Src antibody
N2-17 (1:750 dilution of ascites, a kind gift from T Hunter, Salk
Institute, CA, USA) or anti-human vinculin (10 mgm l
71, Sigma).
Antibody detection was with FITC-conjugated goat anti-mouse IgG
(7.5 mgm l
71, Jackson Laboratories, Bar Harbor, MN, USA) for
45 min at room temperature. Cells were visualised using a confocal
microscope (model MRC600; BioRad Labs, Hercules, CA, USA).
Adhesion assay
96-well plastic plates (Falcon, Becton Dickinson, Oxnard, CA, USA)
were coated with human ﬁbronectin (Becton Dickinson), poly-L-
lysine, vitronectin, laminin or type IV human collagen (all from
Sigma). 0.1% bovine serum albumen (BSA) was added for 2 h at
378C to block non-speciﬁc binding. Negative control wells were
uncoated but blocked with BSA. Cells were suspended in complete
medium and labelled with 90 mCi Chromium-51 (Amersham, Buck-
inghamshire, UK) at 378C for 1 h with regular mixing. After washing
four times in serum-free medium (0.5%), cells were resuspended in
low-serum medium at 2.5610
4 ml
71and 50 ml
71 added to each
well. The plates were incubated for 45 min at 378C then the wells
were gently washed twice with cold PBS. Individual wells were cut
from the plate and the number of attached cells measured by gamma
scintigraphy. A known number of cells was also counted in suspen-
sion in order to calibrate the activity per cell. Non-speciﬁc
attachment was determined on the serum albumen-coated wells
and this ﬁgure subtracted from the experimental values.
RESULTS
Elevated c-Src expression and cellular activity in metastatic
cells from the Fidler model of colon cancer metastasis
Most of the molecular studies on Src family kinases (SFKs) have
been carried out in ﬁbroblasts. Consequently, much less is known
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ous transformation in humans. We set out to address how elevated
c-Src contributes to the behaviour of colon cancer cells, speciﬁcally
examining cell growth and adhesion to extracellular matrix compo-
nents. For these experiments we used cell lines from the Fidler
model of colorectal metastasis (Morikawa et al, 1988). In this
model, cells that have low intrinsic capacity to metastasise to the
liver after intrasplenic injection (KM12C) were compared with
derivative cell lines that have much greater metastatic capacity in
this assay (KM12SM and KM12L4A). The generation and charac-
terisation of these cell lines has been described (Morikawa et al,
1988). Importantly, we conﬁrmed that the actual cells we used in
our studies retained the characteristics of originally reported Fidler
cell lines with respect to metastatic capacity (not shown), and the
acquisition of metastatic potential correlated with elevated c-Src
expression (Figure 1A, upper panel). By using an antibody that
reacts speciﬁcally with active c-Src when it is autophosphorylated
at tyrosine-416, we showed that a parallel increase in c-Src activity
occurred during metastatic conversion (Figure 1A, lower panel;
similar ﬁnding reported in (Mao et al, 1997)). This indicated that
the elevated c-Src protein in the metastatic cells was active. We also
found that tyrosine phosphorylation of paxillin, a focal adhesion
protein that is a substrate of c-Src in colon cancer cells (Rodina
et al, 1999), was elevated in the metastatic cell lines (shown for
KM12L4A in Figure 1B), implying that the additional c-Src protein
was active at peripheral sites. Thus, metastatic potential of these
colon cancer cells correlates with elevated c-Src expression and
activity.
Elevated c-Src is not linked to growth enhancement
We examined KM12C cell growth in vitro, and compared with the
metastatic counterparts (KM12L4A and KM12SM) (Figure 2A).
We did not observe enhanced growth of the metastatic variants
that expressed elevated levels of c-Src; in fact, these cells increased
in number less rapidly than the parental non-metastatic cells
(Figure 2A). We also found both the non-metastatic and metastatic
cells grew similarly under anchorage-independent conditions, one
of the recognised in vitro hallmarks of malignant cells (Figure
2B). In addition, we found similar growth rate of tumours that
arose after subcutaneous inoculation of nude mice with non-meta-
static or metastatic cells (Figure 2C). Thus, elevated expression and
activity of c-Src in the metastatic cells did not correlate with
increased growth in vitro or in vivo.
Elevated c-Src is associated with integrin adhesion
assembly in metastatic cells
As well as growth responses in ﬁbroblasts (reviewed in Abram and
Courtneidge, 2000), SFKs also inﬂuence cell adhesion in both
ﬁbroblasts (Fincham and Frame, 1998) and osteoclasts (Schwartz-
berg et al, 1997). We found that cultures of KM12L4A metastatic
cells contained substantially more vinculin-containing peripheral
adhesion structures than their KM12C non-metastatic counterparts
under normal growth conditions (Figure 3A). Furthermore, the
KM12L4A metastatic cells formed peripheral adhesions more read-
ily when plated on to ﬁbronectin, as compared to their KM12C
non-metastatic counterparts (Figure 3B, right panels). The forma-
tion of clearly discernable vinculin-containing structures was
integrin dependent since these were not formed when the cells were
plated on to poly-L-lysine (Figure 3B, left panels). In addition, the
two metastatic variants, KM12SM and KM12L4A, displayed
substantially greater adhesion to collagen, ﬁbronectin and laminin
than the KM12C non-metastatic counterparts (Figure 3C), while
adhesion to vitronectin was minimal and indistinguishable in all
three cell lines (Figure 3C). Taken together, these data indicate that
elevated expression of c-Src in colon cancer cells from the Fidler
model correlates with enhanced cell–matrix adhesion that is integ-
rin-dependent. Integrin-dependence has now been more precisely
deﬁned by use of inhibitory antibodies to av and b1 integrin subu-
nits that speciﬁcally block adhesion of these colon cancer cells to
ﬁbronectin; cell surface expression of these integrins is not affected
by over-expression of c-Src (not shown).
Short-term treatment with an inhibitor of c-Src suppresses
cell–matrix adhesion
To further probe c-Src’s role in the behaviour of colon cancer cells
from the Fidler model, we used a tyrosine kinase inhibitor (PP2)
that is able to suppress c-Src autophosphorylation on tyrosine-
416, presumably reﬂecting suppression of c-Src activity, and exam-
ined the effects of short-term PP2 treatment of KM12L4A
metastatic cells. At a concentration that effectively inhibited c-Src
autophosphorylation in KM12L4A cells (Figure 4A, upper panel),
PP2 suppressed cell adhesion to ﬁbronectin, but not to poly-L-
lysine (Figure 4A, lower panel), while cell cycle distribution was
not obviously affected (not shown). Thus, although PP2 is not a
speciﬁc inhibitor of c-Src, or SFKs, it is able to effectively suppress
c-Src activity without causing cell cycle withdrawal of KM12C cells.
In addition, we showed that the more recently described selective
Src inhibitor SU6656 (Blake et al, 2000), effectively suppressed
both c-Src kinase activity and adhesion to ﬁbronectin (Figure
4B). Suppression of KM12L4A cell–matrix adhesion by PP2 and
SU6656 is consistent with a role for c-Src in the integrin-induced
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metastatic Metastatic
KM12C
KM12SM
KM12L4A
[expression]
[activity]
Src
Phospho-Src
Blot: anti-Src
IP: anti-Src-phospho-tyr-416
Blot: anti-phosphotyrosine
KM12C
KM12L4A
Phosphopaxillin
Paxillin
Blot: anti-phosphotyrosine
Blot: anti-paxillin
IP: anti-paxillin
A
B
Figure 1 (A) Immunoblots showing expression (upper panel) and activ-
ity (lower panel) of c-Src in the poorly metastatic cell line, KM12C, and in
their highly metastatic derivative cell lines, KM12SM and KM12L4A. Activity
was assessed by reactivity with a phospho-speciﬁc antibody raised against
the region of c-Src containing tyrosine-416, the presumed site of autopho-
sphorylation. (B) Comparison of paxillin tyrosine phosphorylation in
KM12C and KM12L4A cells. Paxillin was immunoprecipitated, blotted
and probed with phosphotyrosine-speciﬁc antibodies (upper panel) or
anti-paxillin (lower panel).
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of cell–matrix adhesion structures in these colon cancer cells.
Enforced expression of activated c-Src in the KM12C
non-metastatic cells does not inﬂuence cell growth but
stimulates assembly of integrin adhesions
To address whether elevated cellular c-Src activity was sufﬁcient to
induce formation of peripheral adhesion structures, we generated
single cell clones of KM12C cells expressing an activated mutant
of c-Src (SrcY527F; clones 2C3 and 2C4 are shown (Figure 5A,
upper panels). We conﬁrmed that expression of activated c-Src
in KM12C cells resulted in enhanced tyrosine phosphorylation of
paxillin, although this was more pronounced in clone 2C4 (Figure
5B, lower panel). We found that KM12C non-metastatic cells
(2CV) grew with similar kinetics to clones expressing c-SrcY527F
(Figure 5B). Furthermore, the doubling times of vector- and c-
SrcY527F-expressing KM12C cells grown in vivo as sub-cutaneous
tumours were not signiﬁcantly different in the mouse strain used
and at the particular number of cells injected (Figure 5C).
However, in contrast to the lack of growth stimulation, we found
that KM12C cells expressing activated c-Src spread more readily
and formed robust peripheral adhesions, as judged by anti-vinculin
staining (Figure 6E and G) or anti-Src staining (Figure 6F and H),
after plating on ﬁbronectin. This effect of c-SrcY527F expression
was not evident when cells were plated on poly-L-lysine (Figure
6C and D), demonstrating integrin dependence. Vector-control
transfected KM12C (2CV) cells spread poorly and remained rela-
tively rounded (compare Figure 6A with E and G). These
ﬁndings indicate that elevated expression of active c-Src in the
non-metastatic KM12C cells is sufﬁcient to confer an enhanced
ability to spread on underlying matrix components by forming
prominent integrin-dependent adhesions. Since this is also
enhanced in the KM12L4A and KM12SM metastatic derivatives
that express elevated c-Src (see Figure 3), it seems likely that this,
rather than enhanced proliferation, may reﬂect the major contribu-
tion of elevated c-Src to metastatic potential in the Fidler model.
DISCUSSION
Altered tyrosine phosphorylation of cellular proteins is associated
with cell transformation, although exactly how individual tyrosine
kinases contribute to aspects of the transformed phenotype in
epithelial cancer cells, remains unclear. One particular oncoprotein
that is frequently linked to colon cancer progression, and indeed to
the progression of other epithelial cancers, is c-Src. Although the
mode of increased c-Src expression and activity is not well under-
stood, and may vary from cancer to cancer, it has been associated
with different stages of colon tumour development, including
metastasis (Bolen et al, 1987; Cartwright et al, 1989, 1990; Tala-
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Figure 2 (A) In vitro growth of KM12C, KM12L4A and KM12SM cells (seeded at 1610
5 cells in 35 mm dishes) was monitored for 14 days. (B) The
ability of KM12C, KM12SM and KM12L4A cells (seeded at 5610
2 cells per ml of medium containing 0.6% agar) to grow when deprived of anchorage
was compared. As control, the colon adenoma cell line RGC2 that does not grow in semi-solid medium was used. Shown are representative areas on
culture dishes. Over a number of experiments, there was no visible difference between the number, or size, of colonies formed by all three cell lines under
anchorage-independent conditions. (C) Subcutaneous primary tumour growth of KM12C, KM12SM and KM12L4A cells was monitored by injecting
2610
6 cells into mice and measuring tumour dimensions at regular intervals. Tumour volumes (upper panel) and doubling times (lower panel) are shown.
4–6 mice were used in each experiment.
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vioural changes that colon cells undergo during malignant or
metastatic transitions is also not deﬁned.
We addressed whether elevated c-Src induced changes in cell
growth or adhesion, both aspects of cell behaviour controlled by
SFKs in ﬁbroblasts that are frequently perturbed in cancer. We
used the Fidler model of colorectal metastasis because it provides
genetically related cell lines that differ in their intrinsic capacity
to metastasise to the liver when injected into the spleen (Morikawa
et al, 1988), and c-Src activity is elevated in the metastatic variants
((Mao et al, 1997); Figure 1A). Growth rate comparisons in vitro,
under both anchorage-dependent and anchorage-independent
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Figure 4 The effects of the Src inhibitory agents PP2 and SU6656 in
KM12L4A cells. (A) PP2 suppresses Src autophosphorylation. c-Src phos-
phorylation on tyrosine-416 in the presence (+) and absence (7)o f
10 mm PP2 for 60 min was determined by immunoprecipitating c-Src, blot-
ting and probing with anti-phospho-tyrosine-416 (upper panels). c-Src ex-
pression was checked by probing blots with anti-Src (lower panels). The
ability of PP2 (at concentrations ranging from 0 to 50 mm) to interfere with
KM12L4A cell attachment to poly-L-lysine or to ﬁbronectin was examined
by Chromium-51 labelling. Suspended, labelled cells were treated with PP2
for 60 min prior to attaching for 60 min (lower panels). (B) SU6656 sup-
presses c-Src kinase activity. The ability of c-Src from cells grown in the pre-
sence and absence of SU6656 to phosphorylate enolase was determined
by in vitro kinase assays (upper panels). The ability of SU6656 to suppress
cell adhesion to ﬁbronectin in 60 min was visualised microscopically and
was quantitated as percentage inhibition of adhesion (lower panels). Bars
are 125 mm.
Normal growth
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Figure 3 (A) Immunoﬂuorescence staining (anti-vinculin) of KM12C and
KM12L4A cells grown under normal culture conditions. Visualisation was by
reaction of primary antibody with FITC-conjugated secondary antibody and
confocal microscopy. Bars are 100 mm. (B) Anti-vinculin staining of KM12C
and KM12L4A cells after plating suspended cells on to poly-L-lysine (left pa-
nels) or ﬁbronectin (right panels) for 60 min. Bars are 100 mm. Similar
images to those shown for KM12L4A cells were obtained for KM12SM
cells. (C) The ability of KM12C, KM12SM and KM12L4A cells to attach
to different matrix components was monitored using Chromium-51-la-
belled cells that were plated on to collagen, ﬁbronectin, laminin or vitronec-
tin for 45 min at 378C. A known number of cells in suspension was also
counted to calibrate the Chromium-51 counts per cell, allowing estimation
of the number of attached cells. The means and standard errors of three
replicates are presented.
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differences that correlated with elevated c-Src (Figure 2). Further-
more, when we expressed an activated mutant of c-Src (c-
SrcY527F) in the non-metastatic cells, growth rates in vitro or in
vivo were not increased (Figure 5), showing that elevating the
intracellular tyrosine kinase activity of c-Src was not sufﬁcient to
promote growth. However, our data does not rule out that some
endogenous c-Src activity might be required for the continued
growth of colon cancer cells. It is possible, perhaps likely, that
the expression and/or activity of c-Src has already been increased
at an earlier stage of tumour progression (Cartwright et al,
1990). In this regard, there is evidence that inhibiting expression
or activity of c-Src can suppress cancer cell growth (Park and Cart-
wright, 1995; Staley et al, 1997; Moasser et al, 1999). Taken
together with our present ﬁndings, these data imply that while
some c-Src activity might be required for proliferation of colon
cancer cells, it is apparently not limiting in carcinoma cells from
the Fidler model since growth is not enhanced by further elevation.
Examination of cell–matrix adhesion revealed that elevated c-
Src correlated with, and resulted in, greater numbers of integrin-
dependent, vinculin-containing peripheral structures in KM12 cells
(Figures 3 and 6). The prominent peripheral adhesions that
contain activated c-Src were dynamically regulated, compared with
the static, more rudimentary peripheral adhesions in the parental
non-metastatic cells, as judged by time-lapse imaging (not shown).
Our recent results also suggest that elevated c-Src de-regulates E-
cadherin-mediated adhesion between colon cancer cells, and that
the integrin adhesion formation we describe here is required for
this effect (Avizienyte et al, 2002). Thus, enhanced assembly of
dynamically regulated cell–matrix adhesions may contribute to
the behaviour of metastatic tumour cells in a number of ways.
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phorylation at tyrosine-416) in KM12C cell clones (2C3 and 2C4) stably
expressing active c-SrcY527F, or vector control (2CV), was examined
and compared with parental KM12C cells and their metastatic derivatives,
KM12SM and KM12L4A. Paxillin phosphorylation in vector- and c-
SrcY527F-expressing KM12C cells was also examined. (B) In vitro growth
of KM12C cells stably expressing active c-SrcY527F (2C3 and 2C4; seeded
at 1610
5 cells in 35 mm dishes) was compared with vector-transfected
cells (2CV). (C) The doubling times of subcutaneous tumours formed after
injection of 10
6 KM12C cells transfected with either vector (2CV) or active
c-SrcY527F (2C3 and 2C4) were determined.
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Figure 6 The effect of increasing cellular c-Src expression and activity on
the formation of adhesion structures in KM12C cells expressing either vec-
tor (2CV; A, B) or active c-SrcY527F (2C3 or 2C4; C–H) were plated on
to ﬁbronectin (A, B, E, F, G, H) or poly-L-lysine (C, D), ﬁxed and stained
with anti-vinculin (A, C, E and G) or anti-Src (B, D, F and H) and exam-
ined by immunoﬂuorescence. Bars are 100 mm.
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including epidermal growth factor (EGF), both to induce epithelial
cell migration (Rodier et al, 1995), as well as to induce hepatocyte
growth factor (HGF)- or EGF-induced invasion of colon cancer
cells in vitro (Brunton et al, 1997; Empereur et al, 1997). Conse-
quently, elevated c-Src activity might facilitate EGF- or HGF-
induced biological effects by reducing the concentration of growth
factor required to elicit an integrin-dependent migratory or inva-
sive response, or render these processes independent of growth
factors. However, expression of activated c-Src was not sufﬁcient
to convert non-metastatic cells into metastatic cells in vivo (not
shown), indicating that while the adhesion changes induced by
elevated c-Src might be contributory, these are not sufﬁcient to
elicit extravasation, attachment and growth at the ectopic liver site.
Although we have studied the role of elevated c-Src expression
here in some detail in the genetically related cells of the Fidler
model, our previous studies in another colon cancer progression
model showed that c-Src itself is redistributed to integrin adhe-
sions, whose formation accompanies acquisition of an invasive
phenotype (Brunton et al, 1997). This together with the established
role for c-Src in the mesenchymal transition of a rat bladder carci-
noma cell line (Rodier et al, 1995), which is associated with loss of
cell–cell and gain of cell–matrix adhesions, suggests that the role
of c-Src in inducing matrix adhesion assembly is not restricted to
cells from the Fidler model. Interestingly, in the rat bladder cancer
model, c-Src is causally linked to the establishment of metastases
(Boyer et al, 2002).
Our results imply that, at least for some advanced colon cancers,
inhibitors of c-Src might be more likely to suppress further tumour
spread than to inhibit tumour growth per se. Consequently, the
conventional endpoints for pre-clinical and early phase clinical
trials that monitor tumour shrinkage might not be the most appro-
priate for testing such agents.
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